The EMBARC European bronchiectasis registry: Protocol for an international observational study

James D. Chalmers, Stefano Aliberti, Eva Polverino, Montserrat Vendrell, Megan Crichton, Michael Loebinger, Katerina Dimakou, Ian Clifton, Menno Van Der Eerden, Gernot Rohde, Marlene Murris-Espin, Sarah Masefield, Eleanor Gerada, Michal Shteinberg, Felix Ringshausen, Charles Haworth, Wim Boersma, Jessica Rademacher, Adam T. Hill, Timothy AksamitAnne O’Donnell, Lucy Morgan, Branislava Milenkovic, Leandro Tramma, Joao Neves, Rosario Menendez, Perluigi Paggiaro, Victor Botnaru, Sabina Skrgat, Robert Wilson, Pieter Goeminne, Anthony De Soyza, Tobias Welte, Antoni Torres, J. Stuart Elborn, Francesco Blasi

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of patients with bronchiectasis. The inclusion criterion is a primary clinical diagnosis of bronchiectasis consisting of: 1) a clinical history consistent with bronchiectasis; and 2) computed tomography demonstrating bronchiectasis. Core exclusion criteria are: 1) bronchiectasis due to known cystic fibrosis; 2) age <18 years; and 3) patients who are unable or unwilling to provide informed consent. The study aims to enrol 1000 patients by April 2016 across at least 20 European countries, and 10 000 patients by March 2020. Patients will undergo a comprehensive baseline assessment and will be followed up annually for u p to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life. Data from the registry will be available in the form of annual reports. and will be disseminated in conference presentations and peer-reviewed publications. The European Bronchiectasis Registry aims to make a major contribution to understanding the natural history of the disease, as well as guiding evidence-based decision making and facilitating large randomised controlled trials.

Original languageEnglish (US)
Article number00081-2015
JournalERS Monograph
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Bronchiectasis
Observational Studies
Registries
Research
Neglected Diseases
Annual Reports
Pulmonary Medicine
Informed Consent
Cystic Fibrosis
Publications
Epidemiologic Studies
Decision Making
Randomized Controlled Trials
Tomography
Quality of Life

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Chalmers, J. D., Aliberti, S., Polverino, E., Vendrell, M., Crichton, M., Loebinger, M., ... Blasi, F. (2016). The EMBARC European bronchiectasis registry: Protocol for an international observational study. ERS Monograph, 2(1), [00081-2015]. https://doi.org/10.1183/23120541.00081-2015

The EMBARC European bronchiectasis registry : Protocol for an international observational study. / Chalmers, James D.; Aliberti, Stefano; Polverino, Eva; Vendrell, Montserrat; Crichton, Megan; Loebinger, Michael; Dimakou, Katerina; Clifton, Ian; Eerden, Menno Van Der; Rohde, Gernot; Murris-Espin, Marlene; Masefield, Sarah; Gerada, Eleanor; Shteinberg, Michal; Ringshausen, Felix; Haworth, Charles; Boersma, Wim; Rademacher, Jessica; Hill, Adam T.; Aksamit, Timothy; O’Donnell, Anne; Morgan, Lucy; Milenkovic, Branislava; Tramma, Leandro; Neves, Joao; Menendez, Rosario; Paggiaro, Perluigi; Botnaru, Victor; Skrgat, Sabina; Wilson, Robert; Goeminne, Pieter; De Soyza, Anthony; Welte, Tobias; Torres, Antoni; Elborn, J. Stuart; Blasi, Francesco.

In: ERS Monograph, Vol. 2, No. 1, 00081-2015, 01.01.2016.

Research output: Contribution to journalArticle

Chalmers, JD, Aliberti, S, Polverino, E, Vendrell, M, Crichton, M, Loebinger, M, Dimakou, K, Clifton, I, Eerden, MVD, Rohde, G, Murris-Espin, M, Masefield, S, Gerada, E, Shteinberg, M, Ringshausen, F, Haworth, C, Boersma, W, Rademacher, J, Hill, AT, Aksamit, T, O’Donnell, A, Morgan, L, Milenkovic, B, Tramma, L, Neves, J, Menendez, R, Paggiaro, P, Botnaru, V, Skrgat, S, Wilson, R, Goeminne, P, De Soyza, A, Welte, T, Torres, A, Elborn, JS & Blasi, F 2016, 'The EMBARC European bronchiectasis registry: Protocol for an international observational study', ERS Monograph, vol. 2, no. 1, 00081-2015. https://doi.org/10.1183/23120541.00081-2015
Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M et al. The EMBARC European bronchiectasis registry: Protocol for an international observational study. ERS Monograph. 2016 Jan 1;2(1). 00081-2015. https://doi.org/10.1183/23120541.00081-2015
Chalmers, James D. ; Aliberti, Stefano ; Polverino, Eva ; Vendrell, Montserrat ; Crichton, Megan ; Loebinger, Michael ; Dimakou, Katerina ; Clifton, Ian ; Eerden, Menno Van Der ; Rohde, Gernot ; Murris-Espin, Marlene ; Masefield, Sarah ; Gerada, Eleanor ; Shteinberg, Michal ; Ringshausen, Felix ; Haworth, Charles ; Boersma, Wim ; Rademacher, Jessica ; Hill, Adam T. ; Aksamit, Timothy ; O’Donnell, Anne ; Morgan, Lucy ; Milenkovic, Branislava ; Tramma, Leandro ; Neves, Joao ; Menendez, Rosario ; Paggiaro, Perluigi ; Botnaru, Victor ; Skrgat, Sabina ; Wilson, Robert ; Goeminne, Pieter ; De Soyza, Anthony ; Welte, Tobias ; Torres, Antoni ; Elborn, J. Stuart ; Blasi, Francesco. / The EMBARC European bronchiectasis registry : Protocol for an international observational study. In: ERS Monograph. 2016 ; Vol. 2, No. 1.
@article{de140702b7914e80a2fa9f218b690362,
title = "The EMBARC European bronchiectasis registry: Protocol for an international observational study",
abstract = "Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of patients with bronchiectasis. The inclusion criterion is a primary clinical diagnosis of bronchiectasis consisting of: 1) a clinical history consistent with bronchiectasis; and 2) computed tomography demonstrating bronchiectasis. Core exclusion criteria are: 1) bronchiectasis due to known cystic fibrosis; 2) age <18 years; and 3) patients who are unable or unwilling to provide informed consent. The study aims to enrol 1000 patients by April 2016 across at least 20 European countries, and 10 000 patients by March 2020. Patients will undergo a comprehensive baseline assessment and will be followed up annually for u p to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life. Data from the registry will be available in the form of annual reports. and will be disseminated in conference presentations and peer-reviewed publications. The European Bronchiectasis Registry aims to make a major contribution to understanding the natural history of the disease, as well as guiding evidence-based decision making and facilitating large randomised controlled trials.",
author = "Chalmers, {James D.} and Stefano Aliberti and Eva Polverino and Montserrat Vendrell and Megan Crichton and Michael Loebinger and Katerina Dimakou and Ian Clifton and Eerden, {Menno Van Der} and Gernot Rohde and Marlene Murris-Espin and Sarah Masefield and Eleanor Gerada and Michal Shteinberg and Felix Ringshausen and Charles Haworth and Wim Boersma and Jessica Rademacher and Hill, {Adam T.} and Timothy Aksamit and Anne O’Donnell and Lucy Morgan and Branislava Milenkovic and Leandro Tramma and Joao Neves and Rosario Menendez and Perluigi Paggiaro and Victor Botnaru and Sabina Skrgat and Robert Wilson and Pieter Goeminne and {De Soyza}, Anthony and Tobias Welte and Antoni Torres and Elborn, {J. Stuart} and Francesco Blasi",
year = "2016",
month = "1",
day = "1",
doi = "10.1183/23120541.00081-2015",
language = "English (US)",
volume = "2",
journal = "ERS Monograph",
issn = "2312-508X",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - The EMBARC European bronchiectasis registry

T2 - Protocol for an international observational study

AU - Chalmers, James D.

AU - Aliberti, Stefano

AU - Polverino, Eva

AU - Vendrell, Montserrat

AU - Crichton, Megan

AU - Loebinger, Michael

AU - Dimakou, Katerina

AU - Clifton, Ian

AU - Eerden, Menno Van Der

AU - Rohde, Gernot

AU - Murris-Espin, Marlene

AU - Masefield, Sarah

AU - Gerada, Eleanor

AU - Shteinberg, Michal

AU - Ringshausen, Felix

AU - Haworth, Charles

AU - Boersma, Wim

AU - Rademacher, Jessica

AU - Hill, Adam T.

AU - Aksamit, Timothy

AU - O’Donnell, Anne

AU - Morgan, Lucy

AU - Milenkovic, Branislava

AU - Tramma, Leandro

AU - Neves, Joao

AU - Menendez, Rosario

AU - Paggiaro, Perluigi

AU - Botnaru, Victor

AU - Skrgat, Sabina

AU - Wilson, Robert

AU - Goeminne, Pieter

AU - De Soyza, Anthony

AU - Welte, Tobias

AU - Torres, Antoni

AU - Elborn, J. Stuart

AU - Blasi, Francesco

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of patients with bronchiectasis. The inclusion criterion is a primary clinical diagnosis of bronchiectasis consisting of: 1) a clinical history consistent with bronchiectasis; and 2) computed tomography demonstrating bronchiectasis. Core exclusion criteria are: 1) bronchiectasis due to known cystic fibrosis; 2) age <18 years; and 3) patients who are unable or unwilling to provide informed consent. The study aims to enrol 1000 patients by April 2016 across at least 20 European countries, and 10 000 patients by March 2020. Patients will undergo a comprehensive baseline assessment and will be followed up annually for u p to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life. Data from the registry will be available in the form of annual reports. and will be disseminated in conference presentations and peer-reviewed publications. The European Bronchiectasis Registry aims to make a major contribution to understanding the natural history of the disease, as well as guiding evidence-based decision making and facilitating large randomised controlled trials.

AB - Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Bronchiectasis Audit and Research Collaboration) registry is a prospective, pan-European observational study of patients with bronchiectasis. The inclusion criterion is a primary clinical diagnosis of bronchiectasis consisting of: 1) a clinical history consistent with bronchiectasis; and 2) computed tomography demonstrating bronchiectasis. Core exclusion criteria are: 1) bronchiectasis due to known cystic fibrosis; 2) age <18 years; and 3) patients who are unable or unwilling to provide informed consent. The study aims to enrol 1000 patients by April 2016 across at least 20 European countries, and 10 000 patients by March 2020. Patients will undergo a comprehensive baseline assessment and will be followed up annually for u p to 5 years with the goal of providing high-quality longitudinal data on outcomes, treatment patterns and quality of life. Data from the registry will be available in the form of annual reports. and will be disseminated in conference presentations and peer-reviewed publications. The European Bronchiectasis Registry aims to make a major contribution to understanding the natural history of the disease, as well as guiding evidence-based decision making and facilitating large randomised controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=85029189050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029189050&partnerID=8YFLogxK

U2 - 10.1183/23120541.00081-2015

DO - 10.1183/23120541.00081-2015

M3 - Article

AN - SCOPUS:85016279520

VL - 2

JO - ERS Monograph

JF - ERS Monograph

SN - 2312-508X

IS - 1

M1 - 00081-2015

ER -